Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-333 Single Ascending Dose Study in Healthy Volunteers
NCT04934124Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ITI-333 in opioid use disorder (OUD) (6 cohorts), sponsored by Intra-Cellular Therapies. Primary endpoints: Percentage of subjects with treatment-emergent adverse events, Change from baseline in systolic and diastolic blood pressure and 6 more. Started Dec 2020; status: completed.
02
Drugs
ITI-333
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04934124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934124.